May 8, 2023 07:10 AM EDTUpdated May 12, 12:27 PM
People
Bioregnum

Re­mem­ber that record biotech IPO par­ty in 2018? There was no ‘hap­pi­ly ever af­ter’

Back in the sum­mer of 2018, Aptinyx $AP­TX was bud­ding with high hopes. Its pre­de­ces­sor com­pa­ny, Nau­rex, had sold to Al­ler­gan so Brent Saun­ders and …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

Drugs are ap­proved — and made avail­able — faster in US than most of EU, da­ta show

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times